Key facts
- Notable investors include Dongyuan Huaxin.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Shenzhen Qianhai Kejing Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Shenzhen Qianhai Kejing Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Shenzhen Qianhai Kejing Biotechnology
Manufacturer of cell-based therapeutic solutions intended for disease prevention and treatment. The company offers to combine cell regeneration technology with DNA methylation and mass spectrometry-based detection, supporting early screening and integrated diagnostic-to-intervention services, home-based rapid testing in collaboration with health platforms, and operates multiple production facilities and third-party clinical labs across China, serving oncology and age-related disease management through a comprehensive prevention-and-treatment infrastructure.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2020
- Website
- cellxpert.cn/
- Ownership
- Privately Held (backing)
Shenzhen Qianhai Kejing Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Shenzhen Qianhai Kejing Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Shenzhen Qianhai Kejing Biotechnology in its N-PORT filings yet. We sweep new filings monthly.